By Ben Glickman

Galapagos said it had entered an agreement with Thermo Fisher Scientific to expand manufacturing of its immune-cell cancer treatment candidate.

The company said that Thermo Fisher had agreed to provide CAR-T manufacturing and kitting services for Galapagos' CAR-T hemato-oncology clinical program in the San Francisco area.

Galapagos in November signed a deal with Landmark Bio to manufacture CAR-T in the Boston area.

Write to Ben Glickman at ben.glickman@wsj.com

(END) Dow Jones Newswires

January 04, 2024 16:29 ET (21:29 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.
Grafico Azioni Galapagos (EU:GLPG)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Galapagos
Grafico Azioni Galapagos (EU:GLPG)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Galapagos